| Year |
Citation |
Score |
| 2022 |
Kasner MT, Halloran MB, Pan J, Ritchie EK, Fetterly GJ, Kramer D, Hangauer DG, Thompson JE. A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia. Investigational New Drugs. PMID 35579731 DOI: 10.1007/s10637-022-01255-1 |
0.323 |
|
| 2019 |
Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, Schihl SA, Fetterly G, Menne S, Minderman H. Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers. 11. PMID 31100868 DOI: 10.3390/Cancers11050681 |
0.415 |
|
| 2018 |
Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, et al. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American Journal of Clinical Oncology. PMID 30418178 DOI: 10.1097/Coc.0000000000000492 |
0.646 |
|
| 2018 |
Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. PMID 30299542 DOI: 10.1002/Cncr.31676 |
0.366 |
|
| 2018 |
Smolinski MP, Bu Y, Clements J, Gelman IH, Hegab T, Cutler DL, Fang JWS, Fetterly G, Kwan R, Barnett A, Lau JYN, Hangauer DG. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). Journal of Medicinal Chemistry. PMID 29617135 DOI: 10.1021/Acs.Jmedchem.8B00164 |
0.343 |
|
| 2018 |
Jackson CGCA, Deva S, Bayston KF, Eden K, McLaren BR, Barlow P, Hung NA, Clarke K, Cutler D, Fetterly G, Kwan MR, Kramer D, Chan WK, Hung T. An open-label, randomized cross-over bioavailability and extension study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours. Journal of Clinical Oncology. 36: 2569-2569. DOI: 10.1200/Jco.2018.36.15_Suppl.2569 |
0.349 |
|
| 2018 |
Ma WW, Azad NS, Lam ET, Diamond JR, Dy GK, Opyrchal M, Gallagher D, Brennen C, Cutler D, Kramer D, Chan WK, Kwan R, Fetterly GJ, Adjei AA, Jimeno A. A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 36: 2526-2526. DOI: 10.1200/Jco.2018.36.15_Suppl.2526 |
0.389 |
|
| 2017 |
Kasner MT, Ritchie EK, Cutler D, Fetterly GJ, Kramer D, Hangauer D, Thompson JE. A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy. Journal of Clinical Oncology. 35: 7043-7043. DOI: 10.1200/Jco.2017.35.15_Suppl.7043 |
0.41 |
|
| 2017 |
Mehta R, Sangameswaran DKG, Bezbatchenko K, Moore J, Gil M, Khoury T, Baldino C, Caserta J, Fetterly G, Lee K, Adjei A, Opyrchal M. Abstract P6-11-10: Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-11-10 |
0.421 |
|
| 2017 |
Jackson CGCA, Deva S, Bayston K, Barlow P, Eden K, Hung N, Fetterly G, Cutler D, Kwan R, Kramer D, Chan W, Hung T. An open-label, randomized cross-over bioavailability study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours Annals of Oncology. 28: x39. DOI: 10.1093/Annonc/Mdx658 |
0.348 |
|
| 2016 |
Nair JR, Caserta J, Belko K, Howell T, Fetterly G, Baldino C, Lee KP. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma. Leukemia. PMID 28008178 DOI: 10.1038/Leu.2016.379 |
0.367 |
|
| 2016 |
Wilton J, Kurenova E, Pitzonka L, Gaudy A, Curtin L, Sexton S, Cance W, Fetterly G. Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. European Journal of Drug Metabolism and Pharmacokinetics. 41: 55-67. PMID 25377246 DOI: 10.1007/S13318-014-0233-6 |
0.422 |
|
| 2016 |
Pundt K, Baldino C, Caserta J, Adjei A, Lee K, Zhu X, Verone-Boyle A, Engler F, Pitzonka L, Fetterly G. Abstract 4824: Synergistic interaction of PIM kinase inhibitor, JP_11646, and cytotoxic or targeted therapies in acute leukemia models Cancer Research. 76: 4824-4824. DOI: 10.1158/1538-7445.Am2016-4824 |
0.407 |
|
| 2016 |
Kirpotin DB, Tipparaju S, Huang ZR, Kamoun WS, Pien C, Kornaga T, Oyama S, Olivier K, Marks JD, Koshkaryev A, Schihl SS, Fetterly G, Schoeberl B, Noble C, Hayes M, et al. Abstract 3912: MM-310, a novel EphA2-targeted docetaxel nanoliposome Cancer Research. 76: 3912-3912. DOI: 10.1158/1538-7445.Am2016-3912 |
0.452 |
|
| 2015 |
Hylander BL, Sen A, Beachy SH, Pitoniak R, Ullas S, Gibbs JF, Qiu J, Prey JD, Fetterly GJ, Repasky EA. Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model. Journal of Controlled Release : Official Journal of the Controlled Release Society. 217: 160-169. PMID 26342663 DOI: 10.1016/J.Jconrel.2015.08.047 |
0.38 |
|
| 2015 |
Infante JR, Benhadji KA, Dy GK, Fetterly G, Ma WW, Bendell J, Callies S, Adjei AA. Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs. 33: 432-9. PMID 25640850 DOI: 10.1007/S10637-015-0207-9 |
0.478 |
|
| 2015 |
Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular Cancer Therapeutics. 14: 513-22. PMID 25519701 DOI: 10.1158/1535-7163.Mct-14-0208 |
0.449 |
|
| 2015 |
Ngamphaiboon N, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Investigational New Drugs. 33: 225-32. PMID 25371323 DOI: 10.1007/S10637-014-0174-6 |
0.479 |
|
| 2015 |
Demant P, Thudium KE, Sepporta MV, Affronti H, Meijer G, Prendergast L, Mathijssen RH, Burhans WC, Ma WW, Hutson A, Fetterly GJ, Dittmar AJ. Comprehensive genetic definition of susceptibility to toxic side effects of irinotecan in mice. Journal of Clinical Oncology. 33: e13566-e13566. DOI: 10.1200/Jco.2015.33.15_Suppl.E13566 |
0.36 |
|
| 2015 |
Bakhribah H, Dy GK, Ma WW, Zhao Y, Opyrchal M, Purmal A, Gollnick S, Brady WE, Fetterly GJ, Ngamphaiboon N, Reungwetwattana T, Jacob SM, O'Hara C, Siedlecki F, Adjei A, et al. A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod in patients (pts) with advanced cancers. Journal of Clinical Oncology. 33: 3063-3063. DOI: 10.1200/Jco.2015.33.15_Suppl.3063 |
0.391 |
|
| 2015 |
Iyer RV, Sexton S, Curtin L, Fetterly G, Maguire O, Minderman H, Toshkov I, Tennant B, Hutson A, Trump DL, Johnson C. Abstract 5144: Low dose sorafenib delays hepatocellular cancer (HCC) development in the woodchuck model of hepatitis B related HCC Cancer Research. 75: 5144-5144. DOI: 10.1158/1538-7445.Am2015-5144 |
0.411 |
|
| 2015 |
Ma WW, Fetterly G, LeVea C, Zhao Y, Dy GK, Iyer R, Tan W, Brady W, Whitworth A, Adjei AA. 2315 A phase Ib study of the FGFR/VEGFR inhibitor dovitinib (D) combined with gemcitabine (G) and Capecitabine (C) in advanced pancreatic cancer patients European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31231-X |
0.359 |
|
| 2014 |
Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6269-76. PMID 25336698 DOI: 10.1158/1078-0432.Ccr-14-1595 |
0.32 |
|
| 2014 |
McCann SE, Edge SB, Hicks DG, Thompson LU, Morrison CD, Fetterly G, Andrews C, Clark K, Wilton J, Kulkarni S. A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers. Nutrition and Cancer. 66: 566-75. PMID 24669750 DOI: 10.1080/01635581.2014.894097 |
0.341 |
|
| 2014 |
Fong MK, Fetterly GJ, McDougald LJ, Iyer RV. Carboplatin pharmacokinetics in a patient receiving hemodialysis. Pharmacotherapy. 34: e9-13. PMID 24037992 DOI: 10.1002/Phar.1354 |
0.387 |
|
| 2014 |
Kim W, Wilton J, Zhang L, Lin AM, Fong L, Friedlander TW, Hsieh AC, Aggarwal RR, Rodvelt TJ, Morse A, Bozeman J, Weinberg VK, Molina A, Mohler J, Fetterly GJ, et al. Activity of abiraterone acetate in metastatic patients with castration-resistant prostate cancer (mCRPC) previously treated with ketoconazole: A prospective phase II study from the prostate cancer clinical trials consortium. Journal of Clinical Oncology. 32: 53-53. DOI: 10.1200/Jco.2014.32.4_Suppl.53 |
0.324 |
|
| 2014 |
Wang ES, Fetterly GJ, Pitzonka L, Brady WE, Tan W, Greene J, Munster D, Vigil C, Mendler JH, Becker MW, Carr-O'Dwyer KM, Wetzler M, Liesveld J. Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia. Journal of Clinical Oncology. 32: 7082-7082. DOI: 10.1200/Jco.2014.32.15_Suppl.7082 |
0.432 |
|
| 2014 |
Kim W, Wilton J, Zhang L, Lin AM, Fong L, Hsieh AC, Friedlander TW, Aggarwal RR, Weinberg VK, Morse A, Bozeman J, Molina A, Fetterly GJ, Mohler J, Szmulewitz RZ, et al. Activity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with ketoconazole (keto): A prospective phase II study from the Prostate Cancer Clinical Trials Consortium. Journal of Clinical Oncology. 32: 5039-5039. DOI: 10.1200/Jco.2014.32.15_Suppl.5039 |
0.361 |
|
| 2014 |
Fetterly GJ, Pitzonka L, Zhao Y, Dy GK, Iyer RV, Taubes S, Perez JR, Culver KW, Wilton J, Mongiardo K, Tan W, Brady WE, Whitworth A, Adjei AA, Ma WW. A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors. Journal of Clinical Oncology. 32: 2603-2603. DOI: 10.1200/Jco.2014.32.15_Suppl.2603 |
0.397 |
|
| 2014 |
Ma WW, Diamond JR, Dy GK, Messersmith WA, Zhao Y, Bui LA, Fetterly GJ, Harning R, Wolfe HR, Pencheva P, Bhowmik S, Divekar G, Lakkad NB, Khopade AJ, DiRaddo AM, et al. A phase I and pharmacokinetic study of a weekly dosing schedule of paclitaxel injection concentrate for nano-dispersion (PICN) in patients with advanced solid tumors. Journal of Clinical Oncology. 32: 2566-2566. DOI: 10.1200/Jco.2014.32.15_Suppl.2566 |
0.378 |
|
| 2014 |
Ramanathan RK, Korn RL, Sachdev JC, Fetterly GJ, Marceau K, Marsh V, Neil JM, Newbold RG, Raghunand N, Prey J, Klinz SG, Bayever E, Fitzgerald JB. Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI) Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct224 |
0.382 |
|
| 2014 |
Ding Y, Lim V, Baldino CM, Caserta J, Flanders Y, Dumas S, Fetterly G, Adjei AA. Abstract 751: Preclinical efficacy of the novel PIM inhibitor, JP_11646, in pancreatic cancer Cancer Research. 74: 751-751. DOI: 10.1158/1538-7445.Am2014-751 |
0.475 |
|
| 2014 |
Pundt KE, Baldino CM, Caserta J, Dumas S, Flanders Y, Wang ES, Fetterly GJ. Abstract 5459: Preclinical efficacy of the novel PIM2 kinase inhibitor, JP_11646, in human acute leukemia models Cancer Research. 74: 5459-5459. DOI: 10.1158/1538-7445.Am2014-5459 |
0.379 |
|
| 2014 |
Pitzonka LB, Gaudy A, Schihl S, Curtin L, Sexton S, Baldino CM, Caserta J, Flanders Y, Dumas S, Fetterly G. Abstract 4647: Investigation of the pharmacokinetic profile of the novel PIM2 inhibitor, JP_11646 Cancer Research. 74: 4647-4647. DOI: 10.1158/1538-7445.Am2014-4647 |
0.439 |
|
| 2013 |
Fetterly GJ, Aras U, Meholick PD, Takimoto C, Seetharam S, McIntosh T, de Bono JS, Sandhu SK, Tolcher A, Davis HM, Zhou H, Puchalski TA. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. Journal of Clinical Pharmacology. 53: 1020-7. PMID 23878055 DOI: 10.1002/Jcph.140 |
0.403 |
|
| 2013 |
Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES. Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia. The Aaps Journal. 15: 662-73. PMID 23550025 DOI: 10.1208/S12248-013-9480-8 |
0.465 |
|
| 2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemotherapy and Pharmacology. 71: 1231-40. PMID 23455452 DOI: 10.1007/S00280-013-2117-X |
0.686 |
|
| 2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemotherapy and Pharmacology. 71: 1219-29. PMID 23455451 DOI: 10.1007/S00280-013-2116-Y |
0.645 |
|
| 2013 |
Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Investigational New Drugs. 31: 967-73. PMID 23361621 DOI: 10.1007/S10637-013-9929-8 |
0.327 |
|
| 2013 |
Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 71: 883-92. PMID 23314737 DOI: 10.1007/S00280-013-2079-Z |
0.315 |
|
| 2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ. Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation. Pharmaceutical Research. 30: 707-13. PMID 23151723 DOI: 10.1007/S11095-012-0909-Z |
0.613 |
|
| 2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ. Interactions of everolimus and sorafenib in pancreatic cancer cells. The Aaps Journal. 15: 78-84. PMID 23054975 DOI: 10.1208/S12248-012-9417-7 |
0.622 |
|
| 2013 |
Fetterly GJ, Gaudy A, Liu B, Meholick PD, Kwan MR, Hangauer DG, Park K, Son J, Bang Y. Application of mechanism-based PKPD model to identify optimal dosing regimens for future development of oraxol. Journal of Clinical Oncology. 31: e13505-e13505. DOI: 10.1200/Jco.2013.31.15_Suppl.E13505 |
0.431 |
|
| 2013 |
Gaudy A, Fetterly GJ, Adjei AA, O'Connor TL, Quinones A, Blanco JG, Ferguson D, Meholick PD, Kalabus J. Investigation of the pharmacogenetic influences of carbonyl reductase on doxorubicin and doxorubicinol in breast cancer patients. Journal of Clinical Oncology. 31: 2594-2594. DOI: 10.1200/Jco.2013.31.15_Suppl.2594 |
0.356 |
|
| 2013 |
Ma WW, Lam ET, Dy GK, Diamond JR, Zhao Y, Bui LA, Fetterly GJ, Abramowitz W, Harning R, Pencheva P, Bhowmik S, Divekar GH, DiRaddo AM, Eckhardt SG, Adjei AA, et al. A pharmacokinetic and dose-escalating study of paclitaxel injection concentrate for nano-dispersion (PICN) alone and with carboplatin in patients with advanced solid tumors. Journal of Clinical Oncology. 31: 2557-2557. DOI: 10.1200/Jco.2013.31.15_Suppl.2557 |
0.434 |
|
| 2013 |
Wang ES, Fetterly G, Brady W, Tan W, Greene J, Gaudy A, Vigil CE, Mendler JH, Becker MW, O'Dwyer K, Liesveld JL, Wetzler M. Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients Blood. 122: 2701-2701. DOI: 10.1182/Blood.V122.21.2701.2701 |
0.467 |
|
| 2013 |
Gaudy A, Wilton J, Curtin L, Kurenova E, Buitrago S, Cance W, Fetterly G. Abstract 3372: Pharmacokinetic analysis of CFAK-C4 in dogs and estimation of first dose in man. Cancer Research. 73: 3372-3372. DOI: 10.1158/1538-7445.Am2013-3372 |
0.395 |
|
| 2012 |
Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling. Leukemia Research. 36: 1410-6. PMID 22884950 DOI: 10.1016/J.Leukres.2012.07.015 |
0.369 |
|
| 2012 |
Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 419-26. PMID 22237261 DOI: 10.1097/Jto.0B013E31823C5B11 |
0.313 |
|
| 2012 |
Ait-Oudhia S, Mager DE, Tomaszewski G, Groman AE, Zagst PD, Fetterly GJ, Iyer RV. Bridging sunitinib exposure to time-to-tumor progression in hepatocellular carcinoma patients with mathematical modeling of an angiogenic biomarker. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E14690 |
0.316 |
|
| 2012 |
Means-Powell JA, Adjei AA, Puzanov I, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Chai F, Lamar M, Schwartz BE, Sosman JA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study. Journal of Clinical Oncology. 30: 8519-8519. DOI: 10.1200/Jco.2012.30.15_Suppl.8519 |
0.378 |
|
| 2012 |
Antonarakis ES, Heath EI, Posadas EM, Harrison MR, Bruce JY, Yu EY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MR, Dyster LM, Carducci MA. A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial. Journal of Clinical Oncology. 30: 4654-4654. DOI: 10.1200/Jco.2012.30.15_Suppl.4654 |
0.34 |
|
| 2012 |
Martell RE, Puzanov I, Ma WW, Santoro A, Dy GK, Goff LW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Simonelli M, Chiang WM, Jarboe J, Schwartz BE, et al. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. Journal of Clinical Oncology. 30: 4117-4117. DOI: 10.1200/Jco.2012.30.15_Suppl.4117 |
0.412 |
|
| 2012 |
Fetterly GJ, Liu B, Senzer NN, Amaravadi RK, Schilder RJ, Martin LP, LoRusso P, Papadopoulos KP, Adjei AA, Zagst PD, McKinlay MA, Weng DE, Graham M. Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. Journal of Clinical Oncology. 30: 3029-3029. DOI: 10.1200/Jco.2012.30.15_Suppl.3029 |
0.467 |
|
| 2012 |
Liu B, Kurenova E, Cance WG, Burns S, Fetterly G. Abstract 3786: Physiologically based pharmacokinetic model of CFAK-C4 disposition in mice for understanding its anti-tumor efficacy Cancer Research. 72: 3786-3786. DOI: 10.1158/1538-7445.Am2012-3786 |
0.364 |
|
| 2012 |
Thudium KE, Wollenberg L, Mavis C, Czuczman MS, Fetterly GJ, Hernandez-Ilizaliturri F. Abstract 3709: Synergistic effects of obatoclax (GX15-070) and bortezomib (BTZ) in non-Hodgkin's lymphoma Cancer Research. 72: 3709-3709. DOI: 10.1158/1538-7445.Am2012-3709 |
0.358 |
|
| 2012 |
Pawaskar DK, Straubinger RM, Fetterly G, Hylander BH, Repasky EA, Ma WW, Jusko WJ. Abstract 3681: Multi-scale analysis of everolimus and sorafenib combination in pancreatic cancer xenografts Cancer Research. 72: 3681-3681. DOI: 10.1158/1538-7445.Am2012-3681 |
0.694 |
|
| 2012 |
Ma WW, Zhang H, Hylander B, LeVea C, Repasky E, Weng D, Burns J, Chunduru S, Graham M, Fetterly G, McKinlay M, Adjei A. Abstract 1939: TL32711, a novel Smac mimetic, exerts significant antitumor efficacy in primary pancreatic adenocarcinoma model Cancer Research. 72: 1939-1939. DOI: 10.1158/1538-7445.Am2012-1939 |
0.45 |
|
| 2012 |
Ma W, Weekes C, Pawaskar D, Fetterly G, Messersmith W, Dy G, Straubinger R, Jusko W, Eckhardt S, Adjei A. 584 Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors European Journal of Cancer. 48: 179. DOI: 10.1016/S0923-7534(20)33076-3 |
0.65 |
|
| 2011 |
Adjei AA, Sosman JA, Martell RE, Dy GK, Goff LW, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, et al. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3034. PMID 28022650 DOI: 10.1200/Jco.2011.29.15_Suppl.3034 |
0.392 |
|
| 2011 |
Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prevention Research (Philadelphia, Pa.). 4: 1938-44. PMID 21846796 DOI: 10.1158/1940-6207.Capr-10-0259 |
0.361 |
|
| 2011 |
Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, ... Fetterly G, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology. 153: 599-611. PMID 21492126 DOI: 10.1111/J.1365-2141.2011.08669.X |
0.336 |
|
| 2011 |
Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Cancer Chemotherapy and Pharmacology. 67: 401-14. PMID 20443003 DOI: 10.1007/S00280-010-1334-9 |
0.335 |
|
| 2011 |
Amaravadi RK, Schilder RJ, Dy GK, Ma WW, Fetterly GJ, Weng DE, Graham MA, Burns JM, Chunduru SK, Condon SM, McKinlay MA, Adjei AA. Abstract LB-406: Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-406 |
0.469 |
|
| 2011 |
Aras UT, Lal D, Zagst P, Fetterly GJ, Wang ES. Abstract 5463: Development of a pharmacokinetic (PK)-pharmacodynamic (PD) model to guide combination-dosing strategies of aflibercept (VEGF Trap) and doxorubicin chemotherapy in a systemic preclinical model of human acute myeloid leukemia Cancer Research. 71: 5463-5463. DOI: 10.1158/1538-7445.Am2011-5463 |
0.414 |
|
| 2011 |
Thudium KE, Haese JD, Karpf A, Fetterly G, Wetzler M. Abstract 5380: Synergistic effects of clofarabine and decitabine in acute myeloid leukemia Cancer Research. 71: 5380-5380. DOI: 10.1158/1538-7445.Am2011-5380 |
0.375 |
|
| 2011 |
Thudium KE, Telang U, Wang P, Diegelman P, Buitrago S, Curtain L, Kurenova E, Cance W, Fetterly G. Abstract 4257: Pharmacokinetics (PK) and tissue penetration of the novel VEGFR-3/FAK inhibitor, Chloropyramine Cancer Research. 71: 4257-4257. DOI: 10.1158/1538-7445.Am2011-4257 |
0.367 |
|
| 2011 |
Pawaskar DK, Straubinger R, Fetterly G, Ma W, Jusko W. Abstract 27: Physiologically based pharmacokinetic model for interactions of sorafenib and everolimus in mice Cancer Research. 71: 27-27. DOI: 10.1158/1538-7445.Am2011-27 |
0.663 |
|
| 2011 |
Kulkarni S, Fetterly G, Morrison C, Adjei A, Andrews C, Edge S, Mukhopadhyay U, Swetzig W, Das G. OT1-03-03: Effect of Tamoxifen Therapy on Inhibition of Tumor Suppressor p53 by Estrogen Receptor. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot1-03-03 |
0.349 |
|
| 2011 |
Fakih M, Groman A, McMahon J, Romano K, Wisniewski M, Wilding G, Fetterly G, Muindi J. 6104 POSTER A Phase II Randomized Study of Two Doses of Vorinostat in Combination With 5-FU/LV in Patients With Refractory Colorectal Cancer (CRC) European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71749-X |
0.38 |
|
| 2010 |
Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, Tian L, Mashtare TJ, Murphy M, Prey J, Wetzler M, Fetterly GJ, Wang ES. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Molecular Cancer Therapeutics. 9: 2737-51. PMID 20924124 DOI: 10.1158/1535-7163.Mct-10-0334 |
0.396 |
|
| 2010 |
Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opinion On Pharmacotherapy. 11: 1943-55. PMID 20586710 DOI: 10.1517/14656566.2010.496453 |
0.412 |
|
| 2010 |
Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3786-94. PMID 20463088 DOI: 10.1158/1078-0432.Ccr-10-0547 |
0.433 |
|
| 2010 |
Khushalani NI, Fetterly GJ, Iyer RV, Litwin A, Brady W, Javle MM. Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. Journal of Clinical Oncology. 28: TPS201-TPS201. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps201 |
0.388 |
|
| 2010 |
Iyer RV, Fetterly GJ, Javle MM, Tan W, Wilding GE, Muindi J, Fakih M, Ramnath N, Johnson CS, Trump DL. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. Journal of Clinical Oncology. 28: e13031-e13031. DOI: 10.1200/Jco.2010.28.15_Suppl.E13031 |
0.381 |
|
| 2010 |
Adjei AA, Sosman JA, Dy GK, Ma W, Fetterly GJ, Skupien D, Means JA, Savage R, Chai F, Puzanov I. A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 28: 3024-3024. DOI: 10.1200/Jco.2010.28.15_Suppl.3024 |
0.469 |
|
| 2010 |
Hylander BL, Sen A, Beachy S, Gibbs J, Pitoniak R, Prey J, Fetterly G, Repasky EA. Abstract LB-380: Apo2L/TRAIL reduces interstitial fluid pressure and enhances gemicitabine uptake in patient pancreatic tumor xenografts Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-380 |
0.395 |
|
| 2010 |
Telang U, Lal D, Zagst PD, Fetterly GJ, Wang ES. Abstract 3581: Investigation of the mechanism of aflibercept mediated modulation of doxorubicin anti-tumor effects in a preclinical model of leukemia: Development of a pharmacokinetic-pharmacodynamic model to guide combination dosing strategies Cancer Research. 70: 3581-3581. DOI: 10.1158/1538-7445.Am10-3581 |
0.416 |
|
| 2009 |
Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15540. PMID 27962309 DOI: 10.1200/Jco.2009.27.15_Suppl.E15540 |
0.357 |
|
| 2009 |
Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R. A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4083. PMID 27961640 DOI: 10.1200/Jco.2009.27.15_Suppl.4083 |
0.424 |
|
| 2009 |
Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3511. PMID 27961307 DOI: 10.1200/Jco.2009.27.15_Suppl.3511 |
0.337 |
|
| 2009 |
Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3189-95. PMID 19383814 DOI: 10.1158/1078-0432.Ccr-08-2999 |
0.422 |
|
| 2009 |
Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience. Oncology. 76: 85-90. PMID 19122466 DOI: 10.1159/000187427 |
0.307 |
|
| 2009 |
Rathnasabapathy C, West K, Fetterly G, Battiwalla M, Smiley SL, Hahn T, Brown K, Arnold K, Syta M, Paplham P, Liu J, McCarthy PL. Pharmacokinetics of Mycophenolic Mofetil and Metabolites in Allogeneic Transplant: Determination of Maximum Dose Schedule and Route of Administration. Blood. 114: 2276-2276. DOI: 10.1182/Blood.V114.22.2276.2276 |
0.389 |
|
| 2008 |
Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5856-63. PMID 18794097 DOI: 10.1158/1078-0432.Ccr-08-1046 |
0.449 |
|
| 2008 |
Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 361-7. PMID 18202410 DOI: 10.1200/Jco.2007.12.0345 |
0.383 |
|
| 2008 |
Fetterly GJ, Owen JS, Stuyckens K, Passarell JA, Zannikos P, Soto-Matos A, Izquierdo MA, Perez-Ruixo JJ. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemotherapy and Pharmacology. 62: 135-47. PMID 17922277 DOI: 10.1007/S00280-007-0583-8 |
0.414 |
|
| 2008 |
Fetterly GJ, Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, Bedrosian CL, Rubin EH, Tolcher AW. Pharmacokinetics of oral deforolimus (AP23573, MK-8669) Journal of Clinical Oncology. 26: 14555-14555. DOI: 10.1200/Jco.2008.26.15_Suppl.14555 |
0.473 |
|
| 2007 |
Fetterly GJ, Owen JS, Stuyckens K, Passarell JA, Zannikos P, Matos AS, Izquierdo MA, Perez-Ruixo JJ. Mechanism-based PKPD model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET- 743) treatment Journal of Clinical Oncology. 25: 2545-2545. DOI: 10.1200/Jco.2007.25.18_Suppl.2545 |
0.393 |
|
| 2007 |
Grasela TH, Fetterly GJ, Dul JL, LeComte D, Grahn AY, Fiedler-Kelly JB, Sherman JW, Damjanov N, Fishman MN, Tan AR. Modeling and simulation of neutropenia to support dosing regimens for liposome-encapsulated paclitaxel easy-to-use (LEP- ETU) Journal of Clinical Oncology. 25: 13011-13011. DOI: 10.1200/Jco.2007.25.18_Suppl.13011 |
0.429 |
|
| 2006 |
Tan AR, Hanauske AR, Gelderblom H, Scheulen ME, Van Warmerdam LJ, Rosing H, Fetterly GJ, Shu VS, Sherman JW, Rubin EH. Results of a clinical pharmacokinetic (PK) bioequivalence (BE) study of liposomal paclitaxel (LEP-ETU) versus paclitaxel (T) in patients with advanced cancer Journal of Clinical Oncology. 24: 2017-2017. DOI: 10.1200/Jco.2006.24.18_Suppl.2017 |
0.393 |
|
| 2005 |
Damjanov N, Fishman MN, Steinberg JL, Fetterly GJ, Haas A, Grahn A, Lauay C, Dul JL, Sherman JW, Rubin EH. Final results of a Phase I study of Liposome Entrapped Paclitaxel (LEP-ETU) in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2048. PMID 27946886 DOI: 10.1200/Jco.2005.23.16_Suppl.2048 |
0.39 |
|
| 2005 |
Desai AA, Mita M, Fetterly GJ, Chang C, Netsch M, Knowles HL, Bedrosian CL, Rowinsky E, Tolcher AW, Ratain MJ. Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3043. PMID 27945796 DOI: 10.1200/Jco.2005.23.16_Suppl.3043 |
0.413 |
|
| 2005 |
Kraut EH, Fishman MN, Lorusso PM, Gordon MS, Rubin EH, Haas A, Fetterly GJ, Cullinan P, Dul JL, Steinberg JL. Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response Journal of Clinical Oncology. 23: 2017-2017. DOI: 10.1200/Jco.2005.23.16_Suppl.2017 |
0.429 |
|
| 2004 |
Kraut EH, Fishman MN, Lorusso PM, Steinberg JL, Nieves JA, Fetterly GJ, Darling IM, Wanaski SP, Dul JL, Sherman JW. Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients Journal of Clinical Oncology. 22: 2501-2501. DOI: 10.1200/Jco.2004.22.90140.2501 |
0.353 |
|
| 2003 |
Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. Aaps Pharmsci. 5: E32. PMID 15198520 DOI: 10.1208/Ps050432 |
0.598 |
|
| 2002 |
Lorenz SA, Bigwarfe PM, Balasubramanian SV, Fetterly GJ, Straubinger RM, Wood TD. Noncovalent dimerization of paclitaxel in solution: evidence from electrospray ionization mass spectrometry. Journal of Pharmaceutical Sciences. 91: 2057-66. PMID 12210052 DOI: 10.1002/Jps.10194 |
0.569 |
|
| 2001 |
Fetterly GJ, Tamburlin JM, Straubinger RM. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharmaceutics & Drug Disposition. 22: 251-61. PMID 11754041 DOI: 10.1002/Bdd.283 |
0.605 |
|
| Show low-probability matches. |